Navigation Links
Models developed from the PLCO may help identify at-risk patients for adverse smoking outcomes
Date:10/26/2012

Risk prediction models developed from an ancillary study of the Prostate Lung Colorectal and Ovarian Cancer Screening Trial (PLCO) may be useful in the public health sector for identifying individuals who are at risk for adverse smoking outcomes, such as relapse among former smokers and continued smoking among current smokers, and those who may benefit from relapse prevention and smoking cessation interventions according to a study published October 26 in the Journal of the National Cancer Institute.

With a projected 226,160 new cases of lung cancer and 160,340 lung cancer deaths expected in the U.S. in 2012, researchers are looking at lung cancer screenings as a way to alter peoples' smoking behaviors. Although smoking abstinence is the most effective way to lower lung cancer mortality, both early detection and treatment of the disease may also lower mortality. Both the PLCO and the National Lung Screening Trial (NLST) have gathered data to determine whether screening can lower lung cancer mortality; however, the effects that screening has on smoking behavior is unknown.

To determine the effects of cancer screening on smoking behavior, Kathryn L. Taylor, Ph.D., of the Lombardi Comprehensive Cancer Center at Georgetown University, and colleagues, gathered data from participants who had completed a baseline questionnaire at PLCO trial enrollment and a supplemental questionnaire 4 years after enrollment, which assessed variables such as family history of cancer, comorbidity, and tobacco use. Multivariable logistic regression models were used to predict smoking status once the supplemental questionnaire was completed.

The researchers found that of the 31,694 former smokers on the baseline questionnaire, 1,042 had relapsed, and of the 6,807 current smokers, 4,439 had continued smoking on the supplemental questionnaire. Both relapse and continued smoking were statistically significantly linked with demographic, medical, and tobacco-related characteristics. "The relapse prediction model had excellent discrimination and calibration and suggested that relapse was more likely among longer-term smokers, recent quitters, smokers of light or ultra-light cigarettes, and pipe or cigar smokers," the researchers write, adding that the success of these models, "suggest important variables that should be considered in the development of effective intervention methods for long-term, heavily dependent smokers who are likely to be well represented in lung cancer-screening programs."


'/>"/>
Contact: Zachary Rathner
Zachary.Rathner@oup.com
301-841-1286
Journal of the National Cancer Institute
Source:Eurekalert

Related medicine news :

1. Genetically-engineered preclinical models predict pharmacodynamic response
2. TRPM7 protein key to breast cancer metastasis in animal models
3. Heterogeneous ER+ breast cancer models allow more accurate drug testing
4. Internists express support for new payment and delivery models as basis for replacing SGR
5. Super Models Line Up to Walk The Catwalk and Celebrate Vogue's Fashion Night Out in LA
6. Strategy developed to improve delivery of medicines to the brain
7. Multi-functional anti-inflammatory/anti-allergic developed by Hebrew University researcher
8. Heroes of Chemistry: Developed new drugs and technology to cut heating and cooling bills
9. Clinical trials start for stroke drug developed by Scripps Research, USC, and ZZ Biotech
10. New Facebook app to detect pedophiles and criminals developed by Ben-Gurion U. researchers
11. National Actos Attorneys File Lawsuit on Behalf of Louisiana Woman who Developed Bladder Cancer Allegedly Due to The Diabetes Drug Actos
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... Seattle, WA (PRWEB) , ... February 05, 2016 ... ... consulting firm, ranked #3 in the 2015 Best in KLAS: Software & Services ... The annual Best in KLAS report independently ranks vendor performance by healthcare ...
(Date:2/5/2016)... ... , ... Stuart Bentkover, MD, FACS is thrilled to announce the ... effective tattoo removal today, Dr. Bentkover is the only doctor in Central Massachusetts to ... has been approved by the Food and Drug Administration (FDA) as a safe and ...
(Date:2/5/2016)... ... ... In sleep, when the defenses of the day are at rest, rejected emotions ... disorders is significant self-criticism, and consequently these patients experience this disease with their feelings, ... for coping with this unease, but also leads to a reservoir of emotions that ...
(Date:2/5/2016)... Ramsey, NJ (PRWEB) , ... February 05, 2016 ... ... Optimizing Primary Care for Patients with Rare Diseases, a continuing medical education (CME) ... conference is the first of its kind—and a first for ACCORD, whose mission ...
(Date:2/5/2016)... ... 2016 , ... –This week, Atascadero water heater company First Call Plumbing ... To view the report, click here or see below. , There ... pros and cons, the type chosen is almost entirely up to personal preference. However, ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... France , Germany , Italy ... ). It includes a 10-year epidemiology forecast for the total prevalent ... sex in these markets. GD epidemiology report is written and developed by ... and market-driven, providing expert analysis of disease trends in the 7MM. ... Italy , Spain , UK, and ...
(Date:2/4/2016)... 2016  The Senior Care Pharmacy Coalition (SCPC) ... Chairman Jason Chaffetz (R-UT) and Ranking ... hearing , "Developments in the Prescription Drug Market," ... questions about abusive pharmacy benefit manager (PBM) pricing ... Ranking Member Elijah Cummings (D-MD) are diligent, serious ...
(Date:2/4/2016)... , Feb. 4, 2016 Wegener ... Global Markets Direct,s, ,Wegener Polyangiitis - Pipeline ... Wegener Polyangiitis,s therapeutic pipeline. This report provides ... Polyangiitis, complete with comparative analysis at various stages, ... (MoA), route of administration (RoA) and molecule type, ...
Breaking Medicine Technology: